First Trust Nasdaq Pharmaceuticals ETFFTXH
FTXH
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
17% more capital invested
Capital invested by funds: $5.78M [Q4 2024] → $6.79M (+$1.01M) [Q1 2025]
6.01% more ownership
Funds ownership: 38.88% [Q4 2024] → 44.89% (+6.01%) [Q1 2025]
5% less funds holding
Funds holding: 21 [Q4 2024] → 20 (-1) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Research analyst outlook
We haven’t received any recent analyst ratings for FTXH.
Financial journalist opinion
Neutral
Seeking Alpha
2 weeks ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Positive
Zacks Investment Research
1 month ago
A Look at Pharma ETFs After Strong Q1 Earnings
Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
Neutral
Seeking Alpha
3 months ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Positive
Zacks Investment Research
10 months ago
Pharma ETFs in Focus Post Solid Q2 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Positive
Zacks Investment Research
1 year ago
A Look at Pharma ETFs Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Positive
Zacks Investment Research
1 year ago
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
Neutral
Zacks Investment Research
1 year ago
A Look at Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Charts implemented using Lightweight Charts™